Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NTRK2 fusion |
| Therapy | Zurletrectinib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK2 fusion | Advanced Solid Tumor | predicted - sensitive | Zurletrectinib | Case Reports/Case Series | Actionable | In a Phase I trial, Zurletrectinib treatment was well tolerated and resulted in an overall response rate of 66.7% (4/6, all partial responses) and a disease control rate of 100% (6/6) in patients with NTRK fusion-positive advanced solid tumors, including one partial response with a measurable decrease in the brain lesion (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3106; NCT04685226). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor. | Full reference... |